448-D 100, 10, 1 [448-D] (ATCC® HB-10895)

Organism: human (B cell); human x mouse (heterohybridoma)  /  Cell Type: hybridoma: B lymphocyte; Epstein-Barr virus (EBV) transforme  / 

Permits and Restrictions

View Permits

Organism human (B cell); human x mouse (heterohybridoma)
Cell Type hybridoma: B lymphocyte; Epstein-Barr virus (EBV) transforme
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2 Cells contain Human Immunodeficiency Virsu type 1 (HIV-1)

Biosafety  classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Age adult
Strain

Strain: BALB/c (myeloma)

Applications
It has broad HIV group specificity and reacts with the HTLV-IIIB, MN and SF-2 strains of HIV-1.
The antibody is specific for the CD4-binding domain of the gp120 protein of HIV-1; it inhibits CD4-rgp120 binding.
The antibody can be used in ELISA and neutralization assays.
Storage Conditions liquid nitrogen vapor phase
Derivation
Antibody producing clones were expanded and fused with SHM-D33 heterohybridoma cells (ATCC CRL-1668).
Clinical Data
Human peripheral blood mononuclear cells from HIV seropositive patients were transformed with Epstein-Barr virus (EBV).
Comments
Human peripheral blood mononuclear cells from HIV seropositive patients were transformed with Epstein-Barr virus (EBV).
Antibody producing clones were expanded and fused with SHM-D33 heterohybridoma cells (ATCC CRL-1668).
The antibody is specific for the CD4-binding domain of the gp120 protein of HIV-1; it inhibits CD4-rgp120 binding. It has broad HIV group specificity and reacts with the HTLV-IIIB, MN and SF-2 strains of HIV-1.
The antibody can be used in ELISA and neutralization assays.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 15%.
Subculturing
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml. Maintain cell density between 1 X 10 exp5 and 2 X 10 exp6 viable cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cryopreservation
Freeze medium: Complete growth medium, 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Temperature: 37.0°C
Isotype IgG1 kappa
Name of Depositor New York University
U.S. Patent Number
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished.
References

Zolla-Pazner S, et al. Human monoclonal antibodies to the CD4-binding domain of HIV, uses thereof and synergistic neutralization of HIV. US Patent 6,241,986 dated Jun 5 2001

Wang H, et al. Human monoclonal and polyclonal anti-human immunodeficiency virus-1 antibodies share a common clonotypic specificity. Eur. J. Immunol. 22: 1749-1755, 1992. PubMed: 1378015

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Zolla-Pazner S, et al. Human monoclonal antibodies to the CD4-binding domain of HIV, uses thereof and synergistic neutralization of HIV. US Patent 6,241,986 dated Jun 5 2001

Wang H, et al. Human monoclonal and polyclonal anti-human immunodeficiency virus-1 antibodies share a common clonotypic specificity. Eur. J. Immunol. 22: 1749-1755, 1992. PubMed: 1378015